Mendus
Logotype for Mendus

Mendus (IMMU) investor relations material

Mendus Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Mendus
Q4 2025 earnings summary11 Feb, 2026

Executive summary

  • Positive long-term survival data from the ADVANCE II trial in MRD-positive AML presented at ASH, supporting broad post-remission positioning of vididencel in AML and CML, and expansion into ovarian cancer.

  • Updated clinical strategy aligns with evolving first-line AML treatments, including venetoclax and azacitidine combinations, and includes two new CML trials and a combination trial in AML with first patient enrollment expected in 2026.

  • Large-scale GMP manufacturing established with NorthX Biologics to support late-stage development and commercialization.

  • Corporate reorganization and staff reduction completed to offset increased clinical trial costs and balance costs ahead of anticipated 2026 trials.

  • ALISON trial in ovarian cancer confirmed safety and feasibility of vididencel as a combination therapy.

Financial highlights

  • Q4 net loss was SEK 41.1 million in 2025 (vs. SEK 38.7 million previously); full-year net loss was SEK 130.7 million in 2025.

  • Cash burn for Q4 was SEK 20.4 million; cash position at year-end was SEK 64.7 million.

  • SEK 52.5 million raised in a directed issue with insider support; SEK 50 million loan facility secured.

  • Cash runway extends into Q1 2027 with current financing and loan facility.

  • No revenue recognized; other operating income mainly from research collaborations and grants.

Capital allocation and financing

  • SEK 52.5 million raised via directed issue with insider support.

  • SEK 50 million loan facility secured with Fenja Capital; SEK 30 million tranche used in January.

  • Cash and cash equivalents at year-end: SEK 64.7 million.

  • Shareholders' equity at year-end: SEK 585.1 million.

DIVA trial's impact on AML registration strategy?
CML TFR strategy: How will it differentiate vididencel?
Future non-dilutive financing milestones?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Mendus earnings date

Logotype for Mendus
Q1 20268 May, 2026
Mendus
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Mendus earnings date

Logotype for Mendus
Q1 20268 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Mendus is a biotechnology company developing immunotherapies for the treatment of cancer. The company focuses on therapies that activate the body’s immune system to target and eliminate cancer cells, based on proprietary technologies. Its operations span clinical development and research. The company is headquartered in Stockholm, Sweden, and its shares are listed on the STO.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage